Piyush Goyal reaffirms India's push for pharma innovation, R&D investment
Synopsis
Commerce Minister Piyush Goyal's meeting with the Indian Pharmaceutical Alliance is more than a courtesy call — it comes as Indian pharma M&A hits an all-time high, with 35 deals worth $13.2 billion in Q2 2026 alone and outbound transactions commanding 96 per cent of total deal value. The government's innovation push is arriving at a moment when Indian companies are already placing big global bets.
Key Takeaways
Commerce Minister Piyush Goyal met the Indian Pharmaceutical Alliance (IPA) delegation, led by President Dr Sharvil Patel , on 28 July .
Discussions focused on boosting R&D investment , clinical research, and advanced therapeutics in India's pharma sector.
In Q2 2026 , the domestic pharma and healthcare sector recorded 65 deals worth $13.9 billion .
Pharma M&A values hit an all-time high , with 35 deals worth $13.2 billion and volumes up 17 per cent quarter on quarter .
Outbound transactions accounted for 96 per cent of total M&A value, reflecting aggressive global expansion by Indian firms.
Union Minister of Commerce and Industry Piyush Goyal on 28 July reaffirmed the Centre's commitment to building a globally competitive and innovation-driven pharmaceutical sector, while keeping affordable healthcare at the core of its policy agenda. The minister made the remarks following a meeting with a delegation from the Indian Pharmaceutical Alliance (IPA).
Key Developments from the Meeting
Goyal met with an IPA delegation led by its President, Dr Sharvil Patel, for what he described as a productive interaction. The discussions centred on strengthening India's pharmaceutical innovation ecosystem by attracting greater investment in research and development (R&D), clinical research, and advanced therapeutics.
The minister also emphasised enhanced collaboration between the government and the pharmaceutical industry to accelerate innovation and sharpen the sector's global competitiveness. He reiterated the government's focus on creating an enabling policy environment that balances innovation incentives with access to affordable medicines.
What the Government Said
Goyal underscored that the government's approach is not a trade-off between innovation and affordability — rather, it sees the two as complementary. The minister's remarks align with a broader policy push to position India as a global hub for pharmaceutical manufacturing and high-value drug development, moving beyond its established identity as the world's generic medicine supplier.
India's Pharma Sector: The Bigger Picture
India is among the largest pharmaceutical producers globally and has long been a critical supplier of affordable generic medicines to international markets. The government has rolled out multiple initiatives in recent years to promote domestic manufacturing, R&D, and innovation across the sector.
In the second quarter of 2026, the domestic pharma and healthcare sector recorded 65 deals worth $13.9 billion, according to industry data. Excluding a landmark $11.8 billion transaction — reportedly the largest overseas acquisition by an Indian pharmaceutical company — overall deal values still rose 12 per cent over the previous quarter.
M&A Activity at an All-Time High
Mergers and acquisitions dominated deal activity, with 35 deals worth $13.2 billion recorded in the quarter. Transaction volumes rose 17 per cent quarter on quarter, with total M&A values reaching an all-time high. Outbound transactions accounted for 96 per cent of total M&A value, signalling aggressive global expansion by Indian pharma firms.
This surge in deal-making comes as Indian companies seek to acquire overseas assets in branded generics, specialty drugs, and biologics — areas the government is also keen to develop domestically. Goyal's engagement with the IPA signals that policy alignment with this ambition is firmly on the agenda.
Point of View
No R&D tax incentive announcements, and no regulatory reform signals. India's pharma sector is already voting with its capital, as record M&A values show, but that activity is largely outbound, meaning the innovation is being acquired abroad rather than built at home. The government's challenge is to convert deal-making momentum into domestic R&D depth — a gap that ministerial meetings alone will not close.
NationPress
29 Jul 2026
Frequently Asked Questions
What did Piyush Goyal discuss with the Indian Pharmaceutical Alliance?
Commerce Minister Piyush Goyal met an IPA delegation led by President Dr Sharvil Patel on 28 July to discuss strengthening India's pharmaceutical innovation ecosystem. Key topics included attracting greater R&D investment, advancing clinical research, and improving the sector's global competitiveness.
What is the Indian Pharmaceutical Alliance (IPA)?
The Indian Pharmaceutical Alliance is a body representing major research-based pharmaceutical companies operating in India. It engages with government on policy issues related to innovation, intellectual property, and the broader development of India's pharma sector.
How did India's pharma sector perform in Q2 2026?
The domestic pharma and healthcare sector recorded 65 deals worth $13.9 billion in the second quarter of 2026, according to industry data. Excluding a single $11.8 billion transaction, overall deal values still rose 12 per cent over the previous quarter.
Why did pharma M&A hit an all-time high in Q2 2026?
Mergers and acquisitions in the pharma sector reached an all-time high in Q2 2026, with 35 deals worth $13.2 billion and transaction volumes up 17 per cent quarter on quarter. Outbound deals — Indian companies acquiring overseas assets — drove 96 per cent of total M&A value, reflecting a push into branded generics, specialty drugs, and biologics.
What is the government's broader goal for the pharmaceutical sector?
The government aims to position India as a global hub for pharmaceutical manufacturing and high-value drug development, while maintaining its role as a supplier of affordable generic medicines. Policy efforts are focused on creating an enabling environment for innovation through R&D incentives, government-industry collaboration, and domestic manufacturing support.
